Increased late urinary toxicity with whole pelvic radiotherapy after prostatectomy

Thompson IM, Tangen CM, Paradelo J, Lucia S, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 2006; 296: 2329-35.10.1001/jama.296.19.2329Search in Google Scholar

Bolla M, van Poppel H, Colette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 52-8.10.1016/S0140-6736(05)67101-2Search in Google Scholar

Wiegel T, Bottke D, Willich H, Piechota H, Souchon R, Stoeckle M, et al. Phase III results of adjuvant radiotherapy (RT) versus »wait and see« (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95). [Abstract]. J Clin Oncol 2005; 23(Part 1 Suppl): 381S.10.1200/jco.2005.23.16_suppl.4513Search in Google Scholar

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcomes of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-41.10.1200/JCO.2006.08.9607Search in Google Scholar

Jani AB, Sokoloff M, Shalhav A, Stadler W. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis. Urology 2004; 64: 976-81.10.1016/j.urology.2004.06.024Search in Google Scholar

Zelefsky MJ, Aschkenasy E, Kelesen S, Leibel SA. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Biol Phys 1997; 39: 327-33.10.1016/S0360-3016(97)00056-4Search in Google Scholar

Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statement on radiation therapy of prostate cancer: guidlines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. American Society for Terapeutic Radiology and Oncology consensus panel. J Clin Oncol 1999; 17: 1155-63.Search in Google Scholar

Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, et al. Guidlines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007; 84: 121-7.10.1016/j.radonc.2007.07.017Search in Google Scholar

Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relaps-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Biol Phys 2007; 69: 54-61.10.1016/j.ijrobp.2007.02.035Search in Google Scholar

Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Biol Phys 2000; 48: 635-42.10.1016/S0360-3016(00)00700-8Search in Google Scholar

Parmar MKB, Machin D. Survival analysis. Chichester: John Wiley&Sons; 1995.Search in Google Scholar

Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton C, Michalski J, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Biol Phys 2007; 68: 1417-23.10.1016/j.ijrobp.2007.01.04917418972Search in Google Scholar

Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW. Effects of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Biol Phys 1998; 42: 501-6.10.1016/S0360-3016(98)00270-3Search in Google Scholar

Jereczek-Fossa BA, Zerini D, Vavassori A. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2008 74: 115-25.10.1016/j.ijrobp.2008.07.057Search in Google Scholar

Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, et al. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relaps or local recurrence after radical prostatectomy. Int J Radiat Biol Phys 2008; 72: 792-8.10.1016/j.ijrobp.2008.05.063Search in Google Scholar

Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume. Int J Radiat Biol Phys 2006; 64: 835-41.10.1016/j.ijrobp.2005.09.003Search in Google Scholar

Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Biol Phys 2007; 69: 1100-9.10.1016/j.ijrobp.2007.04.076Search in Google Scholar

Portelance L, Chao KSC, Grigsby PW, Benet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum and bladder dose in patients with cervical cancer receiving pelvic and para-aortic radiation. Int J Radiat Biol Phys 2001; 51: 261-6.10.1016/S0360-3016(01)01664-9Search in Google Scholar

Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Biol Phys 2000; 48: 1613-21.10.1016/S0360-3016(00)00771-9Search in Google Scholar

Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in bladder and prostate cancer. Eur Urol Suppl 2005; 4: 15-24.10.1016/j.eursup.2005.01.006Search in Google Scholar

Roach M 3rd, Marquez C, Yuo HS. Predicting the risk of lymph node involvement using the pretreatment prostatic specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Biol Phys 1994; 28: 33-7.10.1016/0360-3016(94)90138-4Search in Google Scholar

Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anathomy. Int J Radiat Biol Phys 2005; 63: 1262-9.10.1016/j.ijrobp.2005.07.95216253781Search in Google Scholar

Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-13. Urology 1999; 54: 495-502.10.1016/S0090-4295(99)00186-7Search in Google Scholar

Taussky D, Bae K, Bahary JP. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology 2008; 72: 1125-9.10.1016/j.urology.2007.11.067Search in Google Scholar

Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Biol Phys 1995; 31: 1341-6.10.1016/0360-3016(95)00060-CSearch in Google Scholar

Botros M, Quevedo JF, Miller RC. Angiosarcoma of the liver after multimodality therapy for gallbladder carcinoma. Radiol Oncol 2009; 43: 126-31.10.2478/v10019-009-0012-1Search in Google Scholar

Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008: 42: 207-14.10.2478/v10019-008-0019-zSearch in Google Scholar